Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance
Salvador Alonso, … , Richard J. Jones, Gabriel Ghiaur
Salvador Alonso, … , Richard J. Jones, Gabriel Ghiaur
Published October 24, 2016
Citation Information: J Clin Invest. 2016;126(12):4460-4468. https://doi.org/10.1172/JCI88152.
View: Text | PDF
Research Article Oncology

Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance

  • Text
  • PDF
Abstract

Interactions between multiple myeloma (MM) cells and the BM microenvironment play a critical role in bortezomib (BTZ) resistance. However, the mechanisms involved in these interactions are not completely understood. We previously showed that expression of CYP26 in BM stromal cells maintains a retinoic acid–low (RA-low) microenvironment that prevents the differentiation of normal and malignant hematopoietic cells. Since a low secretory B cell phenotype is associated with BTZ resistance in MM and retinoid signaling promotes plasma cell differentiation and Ig production, we investigated whether stromal expression of the cytochrome P450 monooxygenase CYP26 modulates BTZ sensitivity in the BM niche. CYP26-mediated inactivation of RA within the BM microenvironment prevented plasma cell differentiation and promoted a B cell–like, BTZ-resistant phenotype in human MM cells that were cocultured on BM stroma. Moreover, paracrine Hedgehog secretion by MM cells upregulated stromal CYP26 and further reinforced a protective microenvironment. These results suggest that crosstalk between Hedgehog and retinoid signaling modulates BTZ sensitivity in the BM niche. Targeting these pathological interactions holds promise for eliminating minimal residual disease in MM.

Authors

Salvador Alonso, Daniela Hernandez, Yu-ting Chang, Christian B. Gocke, Megan McCray, Ravi Varadhan, William H. Matsui, Richard J. Jones, Gabriel Ghiaur

×

Figure 1

Expression of B and plasma cell markers in response to retinoid-low or -high conditions.

Options: View larger image (or click on image) Download as PowerPoint
Expression of B and plasma cell markers in response to retinoid-low or -...
(A and B) Relative quantification of BCL6 (B cell marker), BLIMP, XBP1s, and CHOP (plasma cell markers) in H929 cells (A) or CD138+ MM cells (B) from 3 different patient samples incubated for 5 days either in the absence of stroma (Liquid), with or without AGN (RA receptor antagonist, 1 μM), or cocultured with BM mesenchymal cells (Stroma), with or without R115 (CYP26 inhibitor, 1 μM) or IRX (CYP26-resistant retinoid, 1 μM). Expression in untreated liquid conditions was set at 1. (C and D) Flow cytometric analysis of CD138 in H929 cells (C) or primary CD138+ MM cells (D) incubated for 5 days in the absence of stroma (Liquid), with or without AGN, or in the presence of BM mesenchymal cells (Stroma), with or without R115 (1 μM) or IRX (1 μM). Data are representative of 3 independent experiments with similar results and represent the mean ± SEM. *P ≤ 0.05 and **P ≤ 0.01, by repeated-measures 1-way ANOVA for determination of statistical significance between groups; P values were corrected for multiple comparisons using Dunnett’s test. Ctrl, control; max, maximum.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts